Iterum Therapeutics plc

NasdaqCM:ITRM Stock Report

Market Cap: US$38.0m

Iterum Therapeutics Management

Management criteria checks 3/4

Iterum Therapeutics' CEO is Corey Fishman, appointed in Nov 2015, has a tenure of 9.5 years. total yearly compensation is $1.13M, comprised of 55.7% salary and 44.3% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth $150.77K. The average tenure of the management team and the board of directors is 4.4 years and 4.4 years respectively.

Key information

Corey Fishman

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage55.7%
CEO tenure9.5yrs
CEO ownership0.4%
Management average tenure4.4yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Aug 19
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03

Aug 12

Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate

Jul 11

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

May 06
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Jan 12
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Sep 25
Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy

Jul 05

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Jun 11
It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

May 20
Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

Feb 04
Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Feb 04
This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

CEO Compensation Analysis

How has Corey Fishman's remuneration changed compared to Iterum Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$1mUS$631k

-US$25m

Sep 30 2024n/an/a

-US$31m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$36m

Dec 31 2023US$2mUS$612k

-US$38m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$56m

Mar 31 2023n/an/a

-US$51m

Dec 31 2022US$1mUS$589k

-US$44m

Sep 30 2022n/an/a

-US$44m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

US$4m

Dec 31 2021US$11mUS$573k

-US$92m

Sep 30 2021n/an/a

-US$99m

Jun 30 2021n/an/a

-US$115m

Mar 31 2021n/an/a

-US$135m

Dec 31 2020US$2mUS$561k

-US$52m

Sep 30 2020n/an/a

-US$64m

Jun 30 2020n/an/a

-US$84m

Mar 31 2020n/an/a

-US$99m

Dec 31 2019US$1mUS$551k

-US$103m

Sep 30 2019n/an/a

-US$104m

Jun 30 2019n/an/a

-US$97m

Mar 31 2019n/an/a

-US$85m

Dec 31 2018US$2mUS$495k

-US$77m

Compensation vs Market: Corey's total compensation ($USD1.13M) is above average for companies of similar size in the US market ($USD670.70K).

Compensation vs Earnings: Corey's compensation has been consistent with company performance over the past year.

CEO

Corey Fishman (59 yo)

9.5yrs

Tenure

US$1,133,016

Compensation

Mr. Corey N. Fishman serves as Independent Director at BioSpecifics Technologies Corp. since April 9, 2020. Mr. Fishman has been President, Chief Executive Officer and Director at Iterum Therapeutics plc (...

Leadership Team

NamePositionTenureCompensationOwnership
Corey Fishman
President9.5yrsUS$1.13m0.40%
$ 150.8k
Judith Matthews
Chief Financial Officer9.5yrsUS$677.04k0.024%
$ 8.9k
Michael Dunne
Strategic Advisor & Director4.4yrsUS$135.00k0.64%
$ 242.0k
Tom Loughman
Senior Vice President of Technical Operations4.3yrsno datano data
Louise Barrett
Senior Vice President of Legal Affairs & Secretary4.3yrsno datano data
Steven Aronin
Senior VP & Head of Clinical Developmentno datano datano data

4.4yrs

Average Tenure

59yo

Average Age

Experienced Management: ITRM's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Corey Fishman
President9.5yrsUS$1.13m0.40%
$ 150.8k
Michael Dunne
Strategic Advisor & Director4.4yrsUS$135.00k0.64%
$ 242.0k
Beth Hecht
Independent Director4.2yrsUS$88.50k0.054%
$ 20.7k
David Kelly
Independent Chairman of the Board8.8yrsUS$94.00k0.0072%
$ 2.7k
Joseph Whalen
Directorless than a yearno datano data

4.4yrs

Average Tenure

61.5yo

Average Age

Experienced Board: ITRM's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/05 10:34
End of Day Share Price 2025/05/02 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Iterum Therapeutics plc is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Adnan ButtGuggenheim Securities, LLC
Antonio ArceH.C. Wainwright & Co.
Ami FadiaLeerink Partners LLC